首页> 外文期刊>Science >Evasion of CD8~+ T Cells Is Critical for Superinfection by Cytomegalovirus
【24h】

Evasion of CD8~+ T Cells Is Critical for Superinfection by Cytomegalovirus

机译:CD8〜+ T细胞的逃避对于巨细胞病毒的超感染至关重要

获取原文
获取原文并翻译 | 示例
       

摘要

Cytomegalovirus (CMV) can superinfect persistently infected hosts despite CMV-specific humoral and cellular immunity; however, how it does so remains undefined. We have demonstrated that superinfection of rhesus CMV-infected rhesus macaques (RM) requires evasion of CD8~+ T cell immunity by virally encoded inhibitors of major histocompatibility complex class I (MHC-I) antigen presentation, particularly the homologs of human CMV US2, 3, 6, and 11. In contrast, MHC-I interference was dispensable for primary infection of RM, or for the establishment of a persistent secondary infection in CMV-infected RM transiently depleted of CD8~+ lymphocytes. These findings demonstrate that US2-11 glycoproteins promote evasion of CD8~+ T cells in vivo, thus supporting viral replication and dissemination during superinfection, a process that complicates the development of preventive CMV vaccines but that can be exploited for CMV-based vector development.
机译:尽管巨细胞病毒具有特定的体液和细胞免疫能力,但巨细胞病毒(CMV)仍可以感染持续感染的宿主。但是,如何执行尚不确定。我们已经证明,将恒河猴CMV感染的恒河猴(RM)进行超级感染需要通过主要组织相容性复合物I类(MHC-1)抗原呈递的病毒编码抑制剂,特别是人类CMV US2的同源物,逃避CD8〜+ T细胞免疫。分别参见图3,图6和图11。相反,MHC-1干扰对于RM的原发感染或在短暂性地耗尽CD8 +淋巴细胞的CMV感染的RM中建立持续的继发感染是必要的。这些发现表明,US2-11糖蛋白可促进体内CD8 + T细胞的逃逸,从而支持病毒在超级感染过程中的复制和传播,这一过程使预防性CMV疫苗的开发复杂化,但可用于基于CMV的载体开发。

著录项

  • 来源
    《Science》 |2010年第5974期|p.102-106|共5页
  • 作者单位

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Oregon National Primate Research Center, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA Oregon National Primate Research Center, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA Oregon National Primate Research Center, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA Oregon National Primate Research Center, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

    Vaccine and Gene Therapy Institute, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA Oregon National Primate Research Center, Oregon Health and Science University, 505 Northwest 185th Avenue, Beaverton, OR 97006, USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:31

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号